Consequently, NRF2 activation represents a double-edged sword: while it protects normal cells from oxidative damage, its dysregulation in cancer cells fosters tumor survival and resistance to therapies (Kitamura and Motohashi, 2018). The gene discussed is NFE2L2; the disease is cancer.